Stock MIPH MINAPHARM PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

All News MINAPHARM Pharmaceuticals

Equities

MIPH

EGS380G1C011

End-of-day quote Egyptian Exchange
Other stock markets
 03:30:00 03/06/2024 am IST 		5-day change 1st Jan Change
213.5 EGP 0.00% Intraday chart for MINAPHARM Pharmaceuticals +6.61% -1.92%
30/05 MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
07/04 MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries
AQ
SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia
AQ
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa
AQ
Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)
AQ
Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa
CI
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa
AQ
Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved
AQ
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021
CI
MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
MINAPHARM Pharmaceuticals Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
MINAPHARM Pharmaceuticals Reports Standalone Earnings Results for the Six Months Ended June 30, 2021
CI
MINAPHARM Pharmaceuticals Announces Consolidated Earnings Results for the Quarter Ended March 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIPH Stock
  4. News MINAPHARM Pharmaceuticals